IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis
Immunity · 2025
DOI: 10.1016/j.immuni.2025.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2025. Verfasst von Dominic Denk und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt/Main, Germany; Goethe University Frankfurt, University Hospi…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptors, Interleukin-17, Carcinogenesis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, European Research Council.
Abstract (Originalsprache)
Expression of interleukin (IL)-17 family cytokines is associated with tumor-promoting inflammation. We found that low expression of IL17RA associated with worse prognosis in late-stage colorectal cancer (CRC) patients. Deletion of Il17ra in intestinal epithelial cells (IECs) in a murine model of CRC enhanced epithelial-to-mesenchymal transition (EMT) via increased expression of the epidermal growth factor receptor and subsequent activation of the kinase Src. Yet, these mice were protected from metastatic disease; Il17ra deletion impaired intestinal barrier function and enhanced systemic fungal invasion and associated immunity. However, in macrophages, IL-17RA was required for spleen tyrosine kinase (Syk) activation upon fungal-induced dectin-1 engagement, and Il17ra ablation impaired IL-18 release and protective CD8+ T cell-mediated anti-tumor immunity. Combining recombinant IL-17 and heat-killed Candida albicans rendered colorectal tumors sensitive to α-PD-1 treatment in a model of microsatellite stable (MSS) CRC. Thus, IL-17RA engages two distinct tumor-suppressive mechanisms in CRC, linking EMT and fungal-induced anti-tumor immunity during tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt/Main, Germany; Goethe University Frankfurt, University Hospital, Medical Clinic 1, 60590 Frankfurt/Main, Germany.
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt/Main, Germany.
- Gut Microbes and Health Institute Strategic Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK; Decoding Biodiversity, Earlham Institute, Norwich NR4 7UZ, Norfolk, UK.
- Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt/Main, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Frankfurt Canc…
Förderung
- Biotechnology and Biological Sciences Research Council
- European Research Council
Zitieren
APA
Denk, D., Ramakrishnan, M., Conche, C., Pallangyo, C., Pesic, M., Ceteci, F., Kennel, K. B., Kirisözü, A. C., Engel, E., Mohs, K., Ritter, B., Pardo, A. M., Özkurt, E., Hildebrand, F., Waisman, A., Arkan, M. C., & Greten, F. R. (2025). IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity. https://doi.org/10.1016/j.immuni.2025.02.005
Vancouver
Denk D, Ramakrishnan M, Conche C, Pallangyo C, Pesic M, Ceteci F, et al. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity. 2025. doi:10.1016/j.immuni.2025.02.005
BibTeX
@article{Denk2025,
author = {Denk, Dominic and Ramakrishnan, Mallika and Conche, Claire and Pallangyo, Charles and Pesic, Marina and Ceteci, Fatih and Kennel, Kilian B and Kirisözü, Asude C and Engel, Esther and Mohs, Kathleen and Ritter, Birgit and Pardo, Angeles Macias and Özkurt, Ezgi and Hildebrand, Falk and Waisman, Ari and Arkan, Melek C and Greten, Florian R},
title = {IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis},
journal = {Immunity},
year = {2025},
doi = {10.1016/j.immuni.2025.02.005}
}
EUVIMED